Cellectis to Report Second Quarter Financial Results on August 6, 2026
| The Manila Times
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the 'Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.